Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-10-31 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Receives EIR from U.S. FDA for its Mandideep Unit-2 Manufacturing Facility.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for Lupin Limited's Mandideep Unit-2 manufacturing facility. It is a disclosure pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015. The document is short (4211 characters) and primarily serves as an announcement of a regulatory inspection outcome rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2023-10-31 English
Earnings Call for Q2 FY24 is scheduled to be held on Thursday, November 9, 2023, at 19.00 hrs (IST).
Regulatory Filings
2023-10-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter addressed to stock exchanges informing about a scheduled earnings call for the second quarter of fiscal year 2024. It references the regulatory requirement under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and states that transcripts of the call will be filed later. The document itself is an announcement of the earnings call event, not the earnings release or the transcript. The document length is short (1605 characters), and it does not contain any financial data or results. Therefore, it is best classified as a Call Transcript (CT) announcement or related to the earnings call event. Since it is announcing the earnings call, the best fitting category is Call Transcript (CT), which covers full text transcripts of company conference calls and related announcements about such calls.
2023-10-31 English
Intimation regarding loss of share certificates by shareholders.
Regulatory Filings Classification · 95% confidence The document text is extremely short (1067 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report types. There is no mention of any report, meeting, or financial data. The content appears to be a certification or attestation by an individual, likely an officer or authorized signatory, but it does not contain actual financial or operational data. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2023-10-31 English
Loss of Share Certificates
Regulatory Filings Classification · 90% confidence The document text is extremely short (1067 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report types. There is no indication of a report, announcement, or detailed information. Given the lack of content and the presence of digital signatures only, this document does not fit any specific report category and is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous filings.
2023-10-31 English
Intimation regarding loss of share certificate by shareholders.
Regulatory Filings Classification · 95% confidence The document text is extremely short (1016 characters) and consists solely of digital signature information by an individual named Rajvardhan Vishnu Satam. There is no substantive content related to financial data, company reports, announcements, or any regulatory filings. The text appears to be a certification or attestation by an officer or individual, without any accompanying report or announcement. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2023-10-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.